APA

Daenen S., Löwenberg B., Sonneveld P., van Putten W. L., Verhoef G., Verdonck L. F., van Veldhoven M. & Huijgens P. C. (19940218). Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). : Leukemia.

Chicago

Daenen S, Löwenberg B, Sonneveld P, van Putten W L, Verhoef G, Verdonck L F, van Veldhoven M and Huijgens P C. 19940218. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). : Leukemia.

Harvard

Daenen S., Löwenberg B., Sonneveld P., van Putten W. L., Verhoef G., Verdonck L. F., van Veldhoven M. and Huijgens P. C. (19940218). Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). : Leukemia.

MLA

Daenen S, Löwenberg B, Sonneveld P, van Putten W L, Verhoef G, Verdonck L F, van Veldhoven M and Huijgens P C. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). : Leukemia. 19940218.